bluebird bio, Inc. (BLUE) bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia. PBF Energy Inc. (PBF) PBF Energy Inc., together with its subsidiaries, engages in refining and supplying petroleum products. […]
Read MoreOver the course of my investing career, I have learned to rely on a lot of fundamental data to paint a picture about the underlying strength of any stock I might consider using for a value-based investment. While some fundamental investors prefer to work with easy-to-reference, quick-glance data like earnings per share and price-to-earnings ratios, […]
Read MoreOver the last year, the pandemic has consistently defied attempts to look past its effects and global impact. Variants of the virus sparked multiple infection waves through 2021 that kept hospitalizations high and strained the health care system in general. As 2022 started, some of those effects appear to have tapered enough that the market […]
Read MoreUnum Group (UNM) Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, and Poland. It operates through Unum US, Unum International, Colonial Life, and Closed Block segments. Kellogg Company (K) Kellogg Company, together with its subsidiaries, manufactures and markets snacks and convenience foods. The company […]
Read MoreNo matter how tired we get of hearing about COVID-19, there is no denying that ever since the virus found its way to American shores more than two years ago, a lot of media attention has been given to the Healthcare sector – and especially to the Biotechnology industry, where many of the biggest names […]
Read More(Bloomberg) — A four-day rebound in biotechnology stocks may be about to gain momentum after an industry ETF rose above a key resistance level, according to the chief strategist at Miller Tabak. The iShares Nasdaq Biotechnology ETF, or IBB, climbed over its 50-day moving average Friday after twice failing to clear the barrier in the […]
Read MoreFor most of the past two years, any examination of the Pharmaceutical industry has necessarily begun and ended with COVID-19 vaccines. Literally, of course, this isn’t true; diseases and viruses of all kinds don’t take a holiday during a pandemic, and so development of existing projects for any company in this industry hasn’t stopped, either. […]
Read MoreNo matter how tired we get of hearing about COVID-19, there is no denying that ever since the virus found its way to American shores, a lot of media attention has been given to the Healthcare sector – and especially to the Biotechnology industry, where many of the biggest names across the world worked nonstop […]
Read More(Bloomberg) — The first year of the Covid-19 pandemic fueled a frenzy for biotechnology stocks. Now, with vaccines in millions of arms and the omicron variant on the wane, there are signs investors are ready to move on. After cresting at nearly $5 billion a month in early 2020, inflows into health-care funds have slowed […]
Read MoreOver the course of my investing career, I have learned to rely on a lot of fundamental data to paint a picture about the underlying strength of any stock I might consider using for a value-based investment. While some fundamental investors prefer to work with easy-to-reference, quick-glance data like earnings per share and price-to-earnings ratios, […]
Read More(Bloomberg) — Meme stocks, blank-check companies and high-flying biotech names that were all the rage at the start of 2021 are now running cold. The first two weeks of the year have brought a 17% tumble for a group of stocks that went public via merger with blank-check firms and a 10% correction for the […]
Read MoreAs recently as last summer, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As new, even more contagious variants of the virus have emerged, however, it has become […]
Read MoreAs I’ve studied the market over the years, one of the intriguing contrasts comes in the way different analysis methods take in the “big picture” of the market. That includes the way that fundamental investors and analysts look at the market versus those that prefer to work on strictly technical terms. I like to work […]
Read MoreKezar Life Sciences, Inc. (KZR) Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials […]
Read MoreBuy Price: $15.00 or better Sell Price: TradersPro Sell Signal Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is […]
Read More